The new laboratory will now enable Evonik to develop and optimise syntheses for HPAPIs in Germany, as well as at the US site.
With the expanded capacity, Evonik now has a reactor volume for HPAPIs of 170m3. Of this, approximately 135m3 are being used for the production of HPAPIs on the metric-ton-scale, and approximately 35m3 for small batch production and manufacturing development quantities.
‘For exclusive synthesis, we can now manufacture the entire spectrum of highly potent active ingredients from the clinical phase to commercialisation,’ said Dr Klaus Stingl, head of the Exclusive Synthesis product line of the company’s newly created Health Care business.
‘The demand for synthesis development and small batch production of HPAPIs for the clinical phase has gone up significantly in the past few years,’ according to Stingl. In part this is due to new developments in the treatment of tumours and endocrine diseases.
The exclusive synthesis of highly potent active ingredients is carried out mainly at the Tippecanoe site, which Evonik acquired from Eli Lilly in 2010. Approximately 650 people are employed at the site.
